Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Not intended for U.S. and UK media

48th Annual Meeting of the American Society of Clinical Oncology (ASCO):

Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012

- First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session
- Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Session

---

Leverkusen, Germany, May 16, 2012 – Bayer HealthCare announced today that data on Nexavar (sorafenib tablets) and several of its investigational oncology compounds will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, in Chicago, IL (USA). These data, including oral presentations of two Late-Breaking Abstracts on the late-stage development compounds regorafenib and Alpharadin (radium-223 chloride), showcase Bayer's commitment to oncology and the potential of its growing pipeline.

"We are pleased to present Phase III data that show progress in Bayer's development of therapies for hard-to-treat, late-stage cancers, where there is a significant need for new treatments," said Kemal Malik, MD, Member of the Bayer HealthCare Executive Committee and Head of Global Development. "At Bayer, we prize innovation and have focused our efforts on a portfolio of oncology compounds with the potential to transform the way cancer is treated."

Notable studies evaluating Bayer's oncology products and compounds at ASCO include:

Regorafenib

- *Randomized Phase 3 trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU) – GRID trial*
    - Late-Breaking Abstract #LBA10008, Oral Abstract Session: Sarcoma
    - Monday, June 4, 5:30 p.m. – 5:45 p.m., Theater S406

- *Phase 3 CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)*
    - Abstract #3502, Oral Abstract Session: Gastrointestinal (Colorectal) Cancer
    - Sunday, June 3, 10:15 a.m. – 10:30 a.m., E Hall D1

Radium-223 chloride (Alpharadin)

- *Final overall survival analysis results from the Phase III, double-blind, randomized, multinational study of radium-223 chloride (Alpharadin) in the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastases (ALSYMPCA)*
    - Late-Breaking Abstract #LBA4512, Oral Abstract Session: Genitourinary (Prostate) Cancer
    - Tuesday, June 5, 10:45 a.m. – 11:00 a.m., E Arie Crown Theater

- *Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) & ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: interim results of a phase III trial (ALSYMPCA)*
    - Abstract #4551, Poster Discussion: Genitourinary (Prostate) Cancer
    - Poster Discussion: Monday, June 4, 11:30 a.m. – 12:30 p.m., E Arie Crown Theater
    - Poster Session: Monday, June 4, 8:00 a.m. – 12:00 p.m., E450A, Poster Board 5

BAY 86-9766

- *A Phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC)*
    - Abstract #4103, General Poster Session: Gastrointestinal (Noncolorectal) Cancer
    - Monday, June 4, 8:00 a.m. – 12:00 p.m., S Hall A2, Poster Board 48F

Regorafenib and Alpharadin are investigational agents and are not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) or other Health Authorities.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Fabian Klingen (+49-214-30-35426)
Ute Menke (+49-214-30-33021)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.